|
| | Publication Year | Title | Author(s) |
| 1 | Mar-2023 | In colon cancer cells fascin1 regulates adherens junction remodeling. | Esmaeilniakooshkghazi, Amin; Pham, Eric; George, Sudeep P; Ahrorov, Afzal; Villagomez, Fabian R; Byington, Michael; Mukhopadhyay, Srijita; Patnaik, Srinivas; Conrad, Jacinta C; Naik, Monali; Ravi, Saathvika; Tebbutt, Niall C ; Mooi, Jennifer K ; Reehorst, Camilla M; Mariadason, John M ; Khurana, Seema |
| 2 | 1-Oct-2022 | Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX. | van Dijk, Erik; van Werkhoven, Erik; Asher, Rebecca; Mooi, Jennifer K ; Espinoza, David; van Essen, Hendrik F; van Tinteren, Harm; van Grieken, Nicole C T; Punt, Cornelis J A; Tebbutt, Niall C ; Ylstra, Bauke |
| 3 | 23-May-2022 | Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. | Luk, Ian Y; Jenkins, Laura J; Schoffer, Kael L; Ng, Irvin; Tse, Janson W T; Mouradov, Dmitri; Kaczmarczyk, Stanislaw; Nightingale, Rebecca; Burrows, Allan D; Anderson, Robin L ; Arango, Diego; Dopeso, Higinio; Croft, Larry; Richardson, Mark F; Sieber, Oliver M; Liao, Yang; Mooi, Jennifer K ; Vukelic, Natalia; Reehorst, Camilla M; Afshar-Sterle, Shoukat ; Whitehall, Vicki L J; Fennell, Lochlan; Abud, Helen E; Tebbutt, Niall C ; Phillips, Wayne A; Williams, David S ; Shi, Wei; Mielke, Lisa A; Ernst, Matthias ; Dhillon, Amardeep S; Clemons, Nicholas J; Mariadason, John M |
| 4 | 24-Jan-2022 | VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. | Chionh, Fiona; Gebski, Val; Al-Obaidi, Sheren J; Mooi, Jennifer K ; Bruhn, Maressa A; Lee, Chee K; Chüeh, Anderly C; Williams, David S ; Weickhardt, Andrew J ; Wilson, Kate; Scott, Andrew M ; Simes, John; Hardingham, Jennifer E; Price, Timothy J; Mariadason, John M ; Tebbutt, Niall C |
| 5 | 15-Apr-2021 | Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. | Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy J; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C |
| 6 | 29-Jan-2021 | Dual anti-angiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study. | Mooi, Jennifer K ; Chionh, Fiona; Savas, Peter; Da Gama Duarte, Jessica; Chong, Geoffrey ; Brown, Stephen; Wong, Rachel; Price, Timothy; Wann, Alysson ; Skrinos, Effie; Mariadason, John M ; Tebbutt, Niall C |
| 7 | 1-Nov-2018 | The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. | Mooi, Jennifer K ; Wirapati, P; Asher, R; Lee, C K; Savas, P S; Price, T J; Townsend, A; Hardingham, J; Buchanan, D; Williams, D ; Tejpar, S; Mariadason, John M ; Tebbutt, Niall C |
| 8 | 2018 | Cell Line Models of Molecular Subtypes of Colorectal Cancer. | Mooi, Jennifer K ; Luk, Ian Y; Mariadason, John M |
Loading...
2
0
20
0
false